[Report] Worldwide Pediatric Drugs Market Research, Trends, Analysis TOC

Chapter One Executive Summary

Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting the World Prescription Pediatric Market
Leading Competitors

Chapter Two Introduction

The Evolution of Child Healthcare
History and Growth of the Pediatric Drug Market
- Absorption
- Distribution
- Biotransformation
- Excretion
Demographics
Treatment Guidelines for Pediatric Populations

Chapter Three Prescription Allergy and Respiratory Drugs

Overview
Description of Conditions and Diseases
- Seasonal Conditions
- Long Term Conditions
- Prevalence and Incidence
Description of Products
- Antihistamines and Combinations
- Antiasthmatic Agents
- Bronchodilators
- Corticosteroids
- Decongestants and Combinations
- Expectorants, Antitussives, and Combinations
- Lung Surfactants
Market Analysis
- Market by Product Type
- Market by Geographical Region
- Competitive Analysis

Chapter Four Prescription Pediatric Anti-Infectives

Overview
Description of Conditions and Diseases
- Respiratory Viral and Bacterial Conditions and Diseases
- Upper Respiratory Tract Infections
- Blood and Immune-Related Bacterial and Viral Infections
- Childhood Diseases
- Urinary Tract Infections (UTI)
- Parasitic Infections
- Miscellaneous Bacterial and Viral Infections
- Prevalence and Incidence
Description of Products
- Antibiotics
- Antifungals
- Anti-Parasitics
- Antivirals
- Miscellaneous Anti-Infectives
Market Analysis
- Market by Product Type
- Market by Geographical Region
Competitive Analysis

Chapter Five Prescription Pediatric Cancer Therapies

Overview
Description of Diseases
- Leukemia
- Lymphomas
- Brain Tumors
- Neuroblastoma
- Osteogenic Sarcoma
- Ewings Sarcoma
- Wilms Tumor
- Rhabdomyosarcoma
- Retinoblastoma
Incidence
Description of Products
- Alkylating Agents
- Antimetabolites
- Antineoplastic Antibiotics
- Mitotic Inhibitors
- Miscellaneous Cancer Therapies
Market Analysis
- Market by Product Type
- Market by Geographical Region
Competitive Analysis

Chapter Six Prescription Pediatric Cardiovascular Drugs

Overview
Description of Conditions and Diseases
- Congenital Heart Disease (CHD)
- Congestive Heart Failure (CHF)
- Hypertension
- Hyperlipidemia/Hypercholesterolemia
- Cardiomyopathy
Prevalence and Incidence
- Congenital Heart Disease
- Congestive Heart Failure
- Hypertension
- Hyperlipidemia/Hypercholesterolemia
- Cardiomyopathy
Description of Products
- Anticoagulants
- Antidysrhythmics
- Antihypertensives
- Cardiac Glycosides
- Miscellaneous Cardiovascular Drugs
Market Analysis
- Market by Product Type
- Market by Geographical Region
- Competitive Analysis

Chapter Seven Prescription Pediatric Central Nervous System Drugs

Overview
Description of Conditions and Diseases
- Epilepsy
- Attention Deficit Hyperactivity Disorder
- Childhood Depression
- Mental Disorders
- Pain
- Anesthesia
- Enuresis
- Juvenile Rheumatoid Arthritis
Prevalence and Incidence
- Attention Deficit Hyperactivity Disorder (ADHD)
- Childhood and Adolescent Depression
- Enuresis
- Epilepsy
- Juvenile Rheumatoid Arthritis
- Other Mental Disorders
Description of Products
- Analgesics and Non-Steroidal Anti-inflammatory Drugs
- Anesthetics
- Antidepressants
- Antipsychotics
- Antiseizure Agents
- Central Nervous Stimulants
- Sedatives, Hypnotics, and Anxiolytics
Miscellaneous Central Nervous System Drugs
Market Analysis
- Market by Product Type
- Market by Geographical Region
Competitive Analysis

Chapter Eight Prescription Pediatric Gastrointestinal Drugs

Overview Description of Conditions and Diseases Chronic Conditions Acute Conditions Prevalence and Incidence Gastroesophageal Reflux (GER) Inflammatory Bowel Disease Peptic Ulcer Disease Irritable Bowel Syndrome Description of Products Antidiarrheals Antiemetics/Emetics Histamine H2 Antagonists Miscellaneous Gastrointestinal Drugs (Including PPIs) Market Analysis Market by Product Type Market by Geographical Region Competitive Analysis

Chapter Nine Prescription Pediatric Hormone Drugs

Overview
Description of Conditions and Diseases
- Hypopituitarism
- Precocious Puberty
- Diabetes Insipidus
- Hypothyroidism
- Hyperthyroidism
- Lymphocytic Thyroiditis
- Diabetes Mellitus
Prevalence and Incidence
- Diabetes Insipidus
- Diabetes Mellitis
- Hyperthyroidism
- Hypopitutitarism
- Hypothyroidism
- Lymphocytic Thyroiditis
- Precocious Puberty
Description of Products
- Antidiabetic Agents
- Antidiuretic Hormones
- Growth Hormone Drugs
- Steroids/Corticosteroids
- Thyroid Drugs
Market Analysis
- Market by Product Type
- Market by Geographical Region
Competitive Analysis

Chapter Ten Other Prescription Pediatric Drugs

Overview
Description of Conditions and Diseases
- Dental
- Dermatological
- Ophthalmic
Prevalence and Incidence
- Acne
- Dental Caries
- Glaucoma
Description of Products
- Dental Products
- Dermatologic Drugs
- Ophthalmic Drugs
- Miscellaneous Drugs
Market Analysis
- Market by Product Type
- Market by Geographical Region
Competitive Analysis

Chapter Eleven Pediatric Research and Development

Overview

Chapter Twelve Issues and Trends Affecting the Pediatric Drug Market

Drug Research and Children
Pediatric Exclusivity Provision
The Pediatric Rule
Clinical Trials for Pediatric Populations
Geographical Issues and Trends
Compliance Issues
Formulation Formula
Off-Label Use of Adult Drugs on Children
Labeling for Pediatric Indications
Marketing Strategies for Manufacturers
- Patent Life Extensions
FDA Initiatives
- Global Initiatives
Pharmaceutical Company Challenges
- Internal Challenges
- Solutions
- External Challenges
Advertising

Chapter Thirteen Total Market Size and Forecast

Overview
Total market Size and Forecast
Markets by Segments
Competitor Analysis
Market Analysis

Chapter Fourteen Corporate Profiles

Introduction Leading Corporate Profiles Abbott Laboratories Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Eli Lilly & Company Genentech, Inc. GlaxoSmithKline Johnson & Johnson Group MedImmune, Inc. Merck & Company, Inc. Novartis Pharmaceuticals Corporation Novo Nordisk Pharmaceuticals, Inc. Pfizer, Inc. Roche Sanofi-Aventis Schering-Plough Corporation Wyeth Other and Emerging Companies at a Glance Alcon Pharmaceuticals Alkermes, Inc. Allergan Antex Biologics Ascent Pediatrics AstraZeneca plc Celltech Group plc Chiron Corporation Daiichi Pharmaceutical Discovery Laboratories, Inc. Elan Corporation plc Genzyme Corporation Targacept (Layton BioSciences) Mallinckrodt Pharmaceuticals Milkhaus Laboratory, Inc. Muro Pharmaceutical, Inc. Nastech Pharmaceutical Company, Inc. Orphan Medical, Inc. Pharmacyclics, Inc. Sepracor, Inc. Shire Pharmaceuticals Group PLC Triangle Pharmaceuticals, Inc. Valeant Pharmaceuticals Vertex Pharmaceuticals, Inc. Appendix Company Directory

list of exhibits

Chapter One

Table 1-1 The World Market for Prescription Pediatric Drugs, 2002-2009
Figure 1-1 The World Market for Prescription Pediatric Drugs, 2002-2009

Chapter Two

Table 2-1 Total World and Regional Pediatric Populations by Age Group 2002-2009
Figure 2-1 World Pediatric Population by Geographic Region 2002, 2004, 2009
Table 2-2 World Pediatric Population by More and Less Developed Countries (in millions) 2002, 2004, 2009
Figure 2-2 World Pediatric Population by More and Less Developed Countries 2002, 2004, 2009
Table 2-3 World Population Distribution by Age Group 2002-2050

Chapter Three

Table 3-1 World Prevalence, Incidence and Mortality of Selected Pediatric Allergy and Respiratory Conditions
Figure 3-1 World Prevalence of Selected Pediatric Respiratory Conditions in Comparison to the Total Pediatric Population
Table 3-2 Selected Prescription Antihistamines and Combinations for Pediatric Administration
Table 3-3 Selected Prescription Antiasthmatics for Pediatric Administration
Table 3-4 Selected Prescription Bronchodilators for Pediatric Administration
Table 3-5 Selected Prescription Corticosteroids for Pediatric Administration
Table 3-6 Selected Prescription Decongestants and Combinations for Pediatric Administration
Table 3-7 Selected Prescription Expectorants for Pediatric Administration
Table 3-8 Selected Prescription Lung Surfactants for Pediatric Administration
Table 3-9 The World Market for Prescription Pediatric Allergy and Respiratory Drugs, 2002-2009
Figure 3-2 The World Market for Prescription Pediatric Allergy and Respiratory Drugs, 2002-2009
Table 3-10 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Product Type (Antihistamines/Combinations, Antiasthmatics, Bronchdilators, Corticosteroids, Decongestants/Combinations, Expectorants/Antitussives/Combinations, Lung Surfectants) 2002-2009
Figure 3-3 The World Market for Prescription Pediatric Allergy and Respiratory Drugs, by Product Type, 2002-2009
Figure 3-4 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Product Type and Percent Distribution, 2002-2009
Figure 3-5 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Percent and Product Type, 2004
Table 3-11 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Geographic Region (U.S. vs. Non-U.S) 2002, 2004, and 2009
Figure 3-6 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Geographic Region, 2002, 2004, and 2009
Table 3-12 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Allergy and Respiratory Drugs, 2004
Figure 3-7 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Allergy and Respiratory Drugs, 2004

Chapter Four

Table 4-1 Global Prevalence, Incidence and Mortality of Selected Viral and Bacterial Infections
Figure 4-1 World Incidence of Selected Pediatric Viral and Bacterial Infections in Comparison to Pediatric Population
Figure 4-2 World Prevalence of Selected Pediatric Viral Infections in Comparison to Total Pediatric Population
Table 4-2 Selected Prescription Antibiotics for Pediatric Administration
Table 4-3 Selected Prescription Antifungals for Pediatric Administration
Table 4-4 Selected Prescription Antiparasitics for Pediatric Administration
Table 4-5 Selected Prescription Anti-virals for Pediatric Administration
Table 4-5 Selected Prescription Anti-virals for Pediatric Administration
Table 4-7 Selected Prescription Miscellaneous Anti-infectives for Pediatric Administration
Table 4-9 The World Market for Prescription Pediatric Drugs: Anti-infectives, 2002-2009
Figure 4-3 The World Market for Prescription Pediatric Drugs: Anti-infectives, 2002-2009
Table 4-8 The World Market for Prescription Pediatric Anti-Infectives by Product Type, 2002-2009
Figure 4-4 The World Market for Prescription Pediatric Anti-Infectives by Product Type 2002-2009
Table 4-9 The World Market for Prescription Pediatric Anti-infectives by Geographic Region, 2002, 2004, and 2009
Figure 4-5 The World Market for Prescription Pediatric Anti-infectives by Geographic Region, 2002, 2004, and 2009
Table 4-10 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Anti-Infectives, 2004
Figure 4-6 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Anti-Infectives, 2004

Chapter Five

Table 5-1 World Incidence of Selected Pediatric Cancers
Figure 5-1 World Incidence of Selected Pediatric Cancers as a Comparison to All Pediatric Cancers
Table 5-2 Selected Prescription Alkylating Agents for Pediatric Administration
Table 5-3 Selected Prescription Antimetabolites for Pediatric Administration
Table 5-4 Selected Prescription Antineoplastic Antibiotics for Pediatric Administration
Table 5-5 Selected Prescription Mitotic Inhibitors for Pediatric Administration
Table 5-6 Selected Prescription Miscellaneous Cancer Therapies for Pediatric Administration
Table 5-7 The World Market for Prescription Pediatric Cancer Therapies, 2002-2009
Figure 5-2 The World Market for Prescription Pediatric Cancer Therapies, 2002-2009
Table 5-8 The World Market for Prescription Pediatric Cancer Therapies, by Product Type 2002-2009
Figure 5-3 The World Market for Prescription Pediatric Cancer Therapies by Product Type, 2002-2009
Figure 5-5 The World Market for Prescription Pediatric Cancer Therapies, Distribution of Revenues by Product Type 2004
Table 5-9 The World Market for Prescription Pediatric Cancer Therapies, by Geographic Region, 2002, 2004, and 2009
Figure 5-6 The World Market for Prescription Pediatric Cancer Therapies by Geographic Region, 2002, 2004, and 2009
Table 5-10 Leading Suppliers Shares of the World Market for Prescription PediatricCancer Therapies, 2004
Figure 5-7 Leading Suppliers Shares of the World Market for Prescription Pediatric Cancer Therapies, 2004

Chapter Six

Table 6-1 World Prevalence, Incidence and Mortality of Cardiovascular Conditions in Pediatric Population
Figure 6-1 World Prevalence of Pediatric Cardiovascular Conditions in Comparison to Pediatric Populations
Table 6-2 Selected Prescription Anticoagluants for Pediatric Administration
Table 6-3 Selected Prescription Antidysrhythmics for Pediatric Administration
Table 6-4 Selected Prescription Antihypertensives for Pediatric Administration
Table 6-5 Selected Prescription Cardiac Glycosides for Pediatric Administration
Table 6-6 Selected Prescription Miscellaneous Cardiovascular Drugs for Pediatric Administration
Table 6-7 The World Market for Prescription Pediatric Drugs: Cardiovascular Drugs, 2002-2009
Figure 6-2 The World Market for Prescription Pediatric Drugs: Cardiovascular Drugs, 2002-2009
Table 6-8 The World Market for Prescription Pediatric Cardiovascular Drugs by Product Type (Anticoagulants, Antidysrhythmics, Antihypertensives, Cardiac Glycosides, Misc) 2002-2009
Figure 6-3 The World Market for Prescription Pediatric Cardiovascular Drugs by Product Type, 2002-2009
Figure 6-4 The World Market for Prescription Pediatric Cardiovascular Drugs, Revenue Distribution by Product Type, 2004
Table 6-9 The World Market for Prescription Pediatric Cardiovascular Drugs by Geographic Region, 2002, 2004, and 2009
Figure 6-5 The World Market for Prescription Pediatric Cardiovascular Drugs by Geographic Region, 2002, 2004, and 2009
Table 6-10 Leading Suppliers Shares of the World Market for Prescription Pediatric Cardiovascular Drugs, 2004
Figure 6-10 Leading Suppliers Shares of the World Market for Prescription Pediatric Cardiovascular Drugs, 2004

Chapter Seven

Table 7-1 World Prevalence of Selected Pediatric Central Nervous System Conditions
Figure 7-1 World Prevalence of Selected Pediatric Central Nervous System Conditions in Comparison to Pediatric Population
Table 7-2 Selected Prescription Analgesic and Non-steroidal Anti-inflammatory Drugs for Pediatric Administration
Table 7-3 Selected Prescription Anesthetics for Pediatric Administration
Table 7-4 Selected Prescription Antidepressants for Pediatric Administration
Table 7-5 Selected Prescription Antipsychotic Drugs for Pediatric Administration
Table 7-6 Selected Prescription Antiseizure Agents for Pediatric Administration
Table 7-7 Selected Prescription Central Nervous Stimulants for Pediatric Administration
Table 7-8 Selected Prescription Sedatives, Hypnotics, and Anxiolytics for Pediatric Administration
Table 7-9 Selected Prescription Miscellaneous Central Nervous System Agents for Pediatric Administration
Table 7-10 The World Market for Prescription Pediatric Central Nervous System Drugs, 2002-2009
Figure 7-2 The World Market for Prescription Pediatric Central Nervous System Drugs, 2002-2009
Table 7-11 The World Market for Prescription Pediatric Central Nervous System Drugs by Product Type (Analgesics/NSAIDs, Anesthetics, Anti-depressants/Antipsychotics, Antiseizure Agents, CNS Stimulants, Sedatives/Hypnotics/Anxiolytics, and Miscellaneous ), 2002-2009
Figure 7-3 The World Market for Prescription Pediatric Central Nervous System Drugs by Product Type, 2002-2009
Figure 7-4 The World Market for Prescription Pediatric Central Nervous System Drugs, Revenue Distribution by Product Type, 2004
Table 7-12 The World Market for Prescription Pediatric Central Nervous System Drugs by Geographic Region 2002, 2004, and 2009
Figure 7-5 The World Market for Prescription Pediatric Central Nervous System Drugs by Geographic Region, 2002, 2004, and 2009
Table 7-13 Leading Suppliers Shares of the World Market for Prescription Pediatric Central Nervous System Drugs, 2004
Figure 7-6 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Central Nervous System Drugs, 2004

Chapter Eight

Table 8-1 Global Prevalence, Incidence, and Mortality of Gastrointestinal Conditions in Pediatric Populations
Figure 8-1 World Incidence of Pediatric Gastrointestinal Conditions in Comparison to Pediatric Population
Figure 8-2 World Prevalence of Pediatric Gastrointestinal Conditions Compared to Pediatric Populations
Table 8-2 Selected Prescription Antidiarrheals for Pediatric Administration
Table 8-3 Selected Prescription Antiemetics/Emetics Drugs for Pediatric Administration
Table 8-4 Selected Prescription Histamine H2 Antagonists for Pediatric Administration
Table 8-5 Selected Prescription Miscellaneous Gastrointestinal Drugs for Pediatric Administration
Table 8-6 The World Market for Prescription Pediatric Gastrointestinal Drugs 2002-2009
Figure 8-3 The World Market for Prescription Pediatric Gastrointestinal Drugs 2002-2009
Table 8-7 The World Market for Prescription Pediatric Gastrointestinal Drugs by Product Type (Antidiarrheals, Antiemetics/Emetics, H2 Antagonists, Misc Drugs incl PPIs) 2002-2009
Figure 8-4 The World Market for Prescription Pediatric Gastrointestinal Drugs by Product Type, 2002-2009
Figure 8-5 The World Market for Prescription Pediatric Gastrointestinal Drugs, Revenue Distribution by Product Type, 2004
Table 8-7 The World Market for Prescription Pediatric Gastrointestinal Drugs by Geographic Region, 2002, 2004, and 2009
Figure 8-6 The World Market for Prescription Pediatric Gastrointestinal Drugs by Geographic Region, 2002, 2004, and 2009
Table 8-8 Leading Suppliers Shares of the World Market for Prescription Pediatric Gastrointestinal Drugs, 2004
Figure 8-11 Leading Suppliers Shares of the World Market for Prescription Pediatric Gastrointestinal Drugs, 2004

Chapter Nine

Table 9-1 World Incidence and Prevalence of Selected Pediatric Hormone Conditions
Figure 9-1 World Incidence of Selected Pediatric Hormone Conditions in Comparison to Pediatric Population
Figure 9-2 World Prevalence of Selected Pediatric Hormone Conditions in Comparison to Pediatric Population
Table 9-2 Selected Prescription Antidiabetic Agents for Pediatric Administration
Table 9-3 Selected Prescription Antidiuretic Hormones for Pediatric Administration
Table 9-4 Selected Prescription Growth Hormone Drugs for Pediatric Administration
Table 9-5 Selected Prescription Steroids/Corticosteroids for Pediatric Administration
Table 9-6 Selected Prescription Thyroid Drugs for Pediatric Administration
Table 9-7 The World Market for Prescription Pediatric Hormone Drugs, 2002-2009
Figure 9-2 The World Market for Prescription Pediatric Hormone Drugs, 2002-2009
Table 9-8 The World Market for Prescription Pediatric Hormone Drugs by Product Type, 2002-2009
Figure 9-3 The World Market for Prescription Pediatric Hormone Drugs by Product Type, 2002-2009
Figure 9-4 The World Market for Prescription Pediatric Hormone Drugs, Revenue Distribution by Product Type, 2004
Table 9-9 The World Market for Prescription Pediatric Hormone Drugs by Geographic Region, 2002, 2004, and 2009
Figure 9-7 The World Market for Prescription Pediatric Drugs: Hormone Drugs, by Geographic Region, 2002, 2004, and 2009
Table 9-10 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Hormone Drugs, 2004
Figure 9-11 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Hormone Drugs, 2004

Chapter Ten

Table 10-1 World Incidence of Other Pediatric Conditions
Figure 10-2 World Incidence/Prevalence of Other Pediatric Conditions in Comparison to Pediatric Populations
Table 10-2 Selected Prescription Dental Products for Pediatric Administration
Table 10-3 Selected Prescription Dermatologic Drugs for Pediatric Administration
Table 10-4 Selected Prescription Ophthalmic Drugs for Pediatric Administration
Table 10-5 Selected Prescription Miscellaneous Drugs for Pediatric Administration
Table 10-6 The World Market for Miscellaneous Pediatric Prescription Drugs 2002-2009
Figure 10-2 The World Market for Miscellaneous Pediatric Prescription Drugs, 2002-2009
Table 10-7 The World Market for Miscellaneous Pediatric Prescription Drugs by Product Type, 2002-2009
Figure 10-3 The World Market for Miscellaneous Pediatric Prescription Drugs by Product Type, 2002-2009
Figure 10-4 The World Market for Miscellaneous Pediatric Prescription Drugs, Revenue Distribution by Product Type 2004
Table 10-8 The World Market for Miscellaneous Pediatric Prescription Drugs, by Geographic Region, 2002, 2004, and 2009
Figure 10-5 The World Market for Miscellaneous Pediatric Prescription Drugs, by Geographic Region, 2002, 2004, and 2009

Chapter Eleven

Table 11-1 Products Recently Approved or in Various Stages of Development for Pediatrics
Table 11-2 Approved Prescription Drugs for which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population
Table 11-3 Approved Prescription Biologics for which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population

Chapter Twelve

Table 12-1 Label Changes for Pediatric Drugs
Table 12-2 FDA Approved Drugs with Pediatric Exclusivity and Patent Expiration Date
Table 12-3 Requests Issued and Received for Pediatric Exclusivity by FDA Review Division as of September, 2005

Chapter Thirteen

Table 13-1 The World Market for Prescription Pediatric Drugs, 2002-2009
Figure 13-1 The World Market for Prescription Pediatric Drugs, 2002-2009
Table 13-2 The World Market for Prescription Pediatric Drugs by Therapeutic Area, 2002-2009
Figure 13-2 The World Market for Prescription Pediatric Drugs by Therapeutic Area, 2002-2009
Figure 13-4 The World Market for Prescription Pediatric Drugs, Revenue Distribution by Therapeutic Area, 2004
Table 13-5 Leading Suppliers Segments of Participation in the World Market for Prescription Pediatric Drugs, 2004

The Worldwide Market for Pediatric Drugs, 2nd Edition

Table of Contents